Aaron Deykin
CIK 2031693 · View on SEC EDGAR ↗
First SEC filing: Oct. 10, 2024 · Latest: June 17, 2026
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 16, 2026 | UPB | S | 895 | $6.10 | $5,460 | 33,197 Direct | -2.63% | Disposed | 19.5% (price as of 2026-08-20) |
| March 16, 2026 | UPB | S | 894 | $9.29 | $8,305 | 32,687 Direct | -2.66% | Disposed | -21.5% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | UPB | Stock Option (Right to Buy) | Common Stock (96,000) | $27.07 | Jan. 1, 2036 | 96,000 | Acquired |
| Feb. 6, 2025 | UPB | Stock Option (Right to Buy) | Common Stock (165,000) | $8.53 | Feb. 5, 2035 | 165,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Oct. 10, 2024 | UPB | Stock Option (Right to Buy)→ Common Stock (279,653) | 279,653 | Direct |
| Oct. 10, 2024 | UPB | Stock Option (Right to Buy)→ Common Stock (182,431) | 182,431 | Direct |
| Oct. 10, 2024 | UPB | Stock Option (Right to Buy)→ Common Stock (16,258) | 16,258 | Direct |
| Oct. 10, 2024 | UPB | Stock Option (Right to Buy)→ Common Stock (11,853) | 11,853 | Direct |
| Oct. 10, 2024 | UPB | Stock Option (Right to Buy)→ Common Stock (107,207) | 107,207 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
UPB
M.D.Chief Medical Officer and Head of Research and Development(6)| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $515,000 | — | — | $1,089,116 | $216,300 | — | $10,500 | $1,830,916 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.